Literature DB >> 30007017

The socioeconomic determinants for transsphenoidal pituitary surgery: a review of New York State from 1995 to 2015.

Sean McKee1, Anthony Yang1, Sarah Kidwai1, Satish Govindaraj1, Raj Shrivastava2, Alfred Iloreta1.   

Abstract

BACKGROUND: Prolonged length of stay (pLOS), disease-related complications, and 30-day readmissions are important quality metrics under the Affordable Care Act. The purpose of our study was to investigate the effect of patient-level and hospital-level factors on these outcomes for patients admitted for transsphenoidal pituitary surgery.
METHODS: The Statewide Planning and Research Cooperative System (SPARCS) database was queried to investigate 30-day readmissions and pLOS for transsphenoidal pituitary surgery in New York from 1995 to 2015. Multivariate logistic regression, adjusting for patient and hospital characteristics, was performed to assess the effect of these variables on the outcomes of interest.
RESULTS: A total of 9950 patients underwent transsphenoidal pituitary surgery; 7122 (72%), 2394 (24%), and 434 (4%) patients were treated at high-volume, medium-volume, and low-volume centers, respectively. Patient factors associated with treatment at high-volume centers (HVCs) included: top income quartile, private insurance, urban residence, and white or Asian race (p < 0.05). Patient variables associated with treatment at low-volume centers (LVCs) included: age >65 years, elevated Charlson comorbidity index (CCI) scores, bottom income quartile, Medicaid and Medicare insurance, rural residence, black race, and Hispanic ethnicity (p < 0.05). Variables predictive of prolonged hospitalizations in our multivariable model included black race, Hispanic ethnicity, Medicaid insurance, low income, female gender, LVC, and comorbidities (panhypopituitarism, hypothyroidism, diabetes insipidus [DI], visual disturbances, CCI) while predictors of readmissions included Asian race, female gender, and comorbidities (Cushing syndrome, DI, CCI).
CONCLUSION: Patients undergoing transsphenoidal pituitary surgery at HVCs have shorter hospitalizations, fewer postoperative electrolyte abnormalities, and lower charges; however, socioeconomic factors may influence access to quality care.
© 2018 ARS-AAOA, LLC.

Entities:  

Keywords:  anterior skull base; endoscopic endonasal approach to the pituitary; endoscopic sinus surgery; health care economics; postoperative; skull base

Mesh:

Year:  2018        PMID: 30007017     DOI: 10.1002/alr.22148

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  5 in total

1.  Endoscopic versus nonendoscopic surgery for resection of pituitary adenomas: a national database study.

Authors:  Khodayar Goshtasbi; Brandon M Lehrich; Mehdi Abouzari; Arash Abiri; Jack Birkenbeuel; Ming-Ying Lan; Wei-Hsin Wang; Gilbert Cadena; Frank P K Hsu; Edward C Kuan
Journal:  J Neurosurg       Date:  2020-03-13       Impact factor: 5.115

2.  The Influence of Hospital Volume on the Outcomes of Nasopharyngeal, Sinonasal, and Skull-Base Tumors: A Systematic Review of the Literature.

Authors:  Stephanie Flukes; Rahul K Sharma; Shivangi Lohia; Marc A Cohen
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-19

Review 3.  Evaluating Equity Through the Social Determinants of Hearing Health.

Authors:  Marissa R Schuh; Matthew L Bush
Journal:  Ear Hear       Date:  2020-06-13       Impact factor: 3.562

4.  Racial Disparities in Acromegaly and Cushing's Disease: A Referral Center Study in 241 Patients.

Authors:  Adriana G Ioachimescu; Neevedita Goswami; Talin Handa; Adlai Pappy; Emir Veledar; Nelson M Oyesiku
Journal:  J Endocr Soc       Date:  2021-11-24

5.  Association between Preoperative Medication Lists and Postoperative Hospital Length of Stay after Endoscopic Transsphenoidal Pituitary Surgery.

Authors:  Mary Saad; Benjamin Salze; Bernard Trillat; Olivier Corniou; Alexandre Vallée; Morgan Le Guen; Aurélien Latouche; Marc Fischler
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.